Williams Dominic P, Park B Kevin
Drug Safety Research Group, Department of Pharmacology and Therapeutics, The University of Liverpool, Liverpool, UK L69 3GE.
Drug Discov Today. 2003 Nov 15;8(22):1044-50. doi: 10.1016/s1359-6446(03)02888-5.
Drugs and chemicals can undergo enzyme-catalyzed bioactivation reactions within cellular systems, with the formation of reactive chemical species. These reactive metabolites can lead to thiol depletion, reversible protein modification (glutathionylation and nitration), further irreversible protein adduct formation and subsequent irreversible protein damage. The incorporation of potentially reactive chemical moieties - toxicophores - within new therapeutic agents should be limited. However, this cannot always be prevented, particularly when the structural feature responsible for toxicity is also responsible for the pharmacological efficacy. The identification and further knowledge of critical levels of thiol depletion and/or covalent modification of protein will aid in the development of new drugs. Importantly, the identification of drug-thiol conjugation should provide a warning of potential problems, yet not hinder the development of a potentially therapeutically useful drug.
药物和化学物质可在细胞系统内发生酶催化的生物活化反应,生成反应性化学物质。这些反应性代谢产物可导致硫醇耗竭、蛋白质可逆性修饰(谷胱甘肽化和硝化)、进一步形成不可逆的蛋白质加合物以及随后的不可逆蛋白质损伤。新治疗药物中潜在反应性化学基团(毒药效团)的引入应受到限制。然而,这并非总能避免,尤其是当导致毒性的结构特征同时也是药理疗效的决定因素时。确定硫醇耗竭和/或蛋白质共价修饰的临界水平并深入了解相关知识,将有助于新药的研发。重要的是,药物 - 硫醇共轭物的鉴定应能警示潜在问题,但不应阻碍具有潜在治疗用途药物的研发。